Clinical Conversations

August 3rd, 2011

Podcast 127: Why QALYs matter

This time we talk with Dr. Katia Noyes, first author on a study of the cost-effectiveness of disease-modifying drugs in multiple sclerosis. If you don’t treat MS, don’t think that the topic is irrelevant. Noyes brings the issues of cost-effectiveness and the dreaded QALY into focus for clinicians who see patients. After all, medical costs will […]

---

January 29th, 2010

Podcast 72: A conversation about two new drugs for multiple sclerosis.

We’ve got Dr. William Carroll this week — we tried last week, but the 13-hour time difference between Boston and Perth just stymied me. Dr. Carroll speaks about his NEJM editorial concerning two new drugs for multiple sclerosis. Both are oral therapies that work to keep lymphocytes at bay in this disease. Interview-story link: MS Treatments Said […]

---